Sage Therapeutics Inc

Most Recent

  • uploads///Chart  NMDA
    Company & Industry Overviews

    What Are Sage Therapeutics’ Receptor-Based Products?

    Sage Therapeutics (SAGE) is focused on the development of the products for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///Marinus risks
    Company & Industry Overviews

    Key Risks Facing Marinus Pharmaceuticals in December 2017

    Since inception in 2003, Marinus Pharmaceuticals (MRNS) has focused on the development of ganaxalone.

    By Kenneth Smith
  • uploads///people _
    Company & Industry Overviews

    Sage’s Brexanolone IV: FDA Grants Priority Review

    On May 30, Sage Therapeutics announced that the FDA accepted the new drug application for Brexanolone IV.

    By Mike Benson
  • uploads///dna _
    Healthcare

    Sage Therapeutics: Analysts’ Estimates and Recommendations

    On July 12, analysts forecast a Q2 net loss of $85.7 million for Sage Therapeutics (SAGE) and a net loss of $377.6 million in fiscal 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    SAGE Therapeutics’ Strategic Collaboration with Shionogi

    On June 13, SAGE Therapeutics announced a strategic collaboration with Shionogi & Company for the development and commercialization of the drug SAGE-217.

    By Mike Benson
  • uploads///laboratory _
    Company & Industry Overviews

    SAGE Therapeutics’ Stock Performance and Estimates in June

    SAGE Therapeutics’ stock price has risen nearly 111.5% in the last 12 months.

    By Mike Benson
  • uploads///pills medical money
    Company & Industry Overviews

    Sage Therapeutics: Results from the Phase 3 ROBIN Trial

    On January 7, Sage Therapeutics presented the results of the Phase 3 ROBIN trial. SAGE-217 met the clinical trial’s primary and secondary endpoints.

    By Daniel Collins
  • uploads///SAGE
    Company & Industry Overviews

    Sage Therapeutics’ Operational Performance

    In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively.

    By Kenneth Smith
  • uploads///nerve cell _
    Company & Industry Overviews

    Sage Therapeutics: Analyzing New Product Candidates

    The Zulresso injection is Sage Therapeutics’ lead product candidate. The company has filed a new drug application.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Here Are the Key Products in Sage’s GABA Receptor Portfolio

    Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Sage Therapeutics’ NMDA Receptor Portfolio

    Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Does Sage Therapeutics’ Product Portfolio Look in September?

    Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.

    By Mike Benson
  • uploads///pills _
    Company & Industry Overviews

    FDA Approves United Therapeutics’ Implantable System for Remodulin

    Today, the FDA approved United Therapeutics’ (UTHR) new drug application for its Remodulin injection used in the Implantable System for Remodulin (or ISR).

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Sage Therapeutics’ NMDA Receptor–Based Products

    Sage Therapeutics developed SAGE-718, which targets the NMDA Receptor.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Sage Therapeutics’ GABA Receptor–Based Products

    On June 12, Sage Therapeutics announced its expedited development plan for SAGE-217.

    By Mike Benson
  • uploads///ganaxalone pre
    Company & Industry Overviews

    Ganaxalone Faces Stiff Competition from Other Drugs under Development

    Marinus Pharmaceuticals (MRNS) has initiated a phase two study to test the feasibility of ganaxalone in patients suffering from refractory status epilepticus (or RSE). Data from this study is expected in 2018.

    By Kenneth Smith
  • uploads///Marinus RD Trend
    Company & Industry Overviews

    Why Ganaxalone Is a Promising Drug Candidate

    Marinus Pharmaceuticals (MRNS) announced phase two results from its open-label study evaluating the efficacy of ganaxalone in patients suffering from CDKL5 deficiency disorder (or CDD) in September 2017.

    By Kenneth Smith
  • uploads///Chart  GABA
    Company & Industry Overviews

    What Are Sage Therapeutics’ GABA Receptor Products?

    The products under development for the treatment of life-threatening central nervous system (or CNS) disorders in Sage Therapeutics’ (SAGE) portfolio are either based on GABA or NMDA receptor systems.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Brexanolone Could Strengthen Ligand’s Neurology Portfolio

    Sage Therapeutics is also exploring Brexanolone in moderate and severe post-partum depression (or PPD) patients in two separate Phase 3 trials.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    What Are IBB’s Holdings’ Moving Averages?

    On May 27, 2016, 17% of the iShares Nasdaq Biotechnology ETF’s (IBB) stocks were trading above their 20-day moving averages.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    iShares Nasdaq Biotechnology ETF (IBB) Had Strong Start to April

    Celldex Therapeutics (CLDX) was the top performer among IBB holdings, rising 10.6% on April 4. The other top performers include Synergy Pharmaceuticals (SGYP) and Sage Therapeutics (SAGE)

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.